US 9617539
Modulation of UBE3A-ATS expression
granted A61PA61P25/00A61P25/28
Quick answer
US patent 9617539 (Modulation of UBE3A-ATS expression) held by Ionis Pharmaceuticals, Inc. expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61P, A61P25/00, A61P25/28, A61P43/00